

Regular Meeting of the WMed Institutional Biosafety Committee (IBC)

August 21, 2025

10:00am - 11:00am

In person Room 423

Meeting Start Time: The Chair confirmed there was a quorum and the meeting was called to order at 10:05am.

Number of Regular members on the roster: 9; Number required for quorum: 5

1. Attendance

Voting Members Present	
Status	Initials
Chair, Member	NH
Member	RV
Member	RP
Member	AC
Member	JD
Member	MC

Voting Members Absent	
Status	Initials
Vice Chair, Member	CJ
Community Member	SF
Community Member	RS

Non-Voting Members Present	
Status	Initials
ISDRC, Ex-officio	CS
IBC Coordinator, Ex-officio	CJK
RSO, Ex-officio	PJ

2. Welcome and Updates

- NH welcomed members to the meeting.
- Introduction of CS as the ISDRC.

3. Conflicts of Interest and Confidentiality

The Chair reminded all members present that any member of the IBC may not participate in the review or approval of a project in which he/she has been or expects to be engaged or has a direct financial interest. NH identified a COI with reviewing their own protocol and will recuse themselves during that portion of the meeting.

4. Review of Prior Minutes

a. Approval of 6.3.2025 minutes

Discussion: No comments.

JD joined at 10:11am during review of meeting minutes.

MOTION: A motion was made by RV and seconded by AC to approve the **6.3.2025** meeting minutes.

VOTES: Approve

# Present	Votes For	Votes Against	Abstained	Recused	Absent
6	6	0	0	0	3

5. Triennial Reviews

a. CJ Protocol Review IBC-2022-024

- **Reviewers:** NH served as primary reviewer and provided an overview; RP was secondary reviewer.
- **Summary:** CJ's protocol focuses on host and viral factors involved in disease caused by cancer-associated viruses. Mice will be infected with MHV68 and subsequently challenged with either *Klebsiella pneumoniae* or a non-typeable *Haemophilus influenzae* strain to evaluate immune responses.
- **Containment:** All work will be conducted at BSL-2 in either the PI's 5th floor laboratory or the BSL-2 vivarium area. Secondary containment will be used for transfers between rooms as needed.
- **Risk Assessment:** Low risk of infection to personnel, as MHV68 infects only mice.
- **Safety Measures:** PPE description is complete and appropriate. SOPs for viral and bacterial strains are attached.

MOTION: A motion was made by NH and seconded by RV to approve

VOTES: Approve

# Present	Votes For	Votes Against	Abstained	Recused	Absent
6	6	0	0	0	3

b. NH Protocol Review IBC-2022-022

- **Reviewers:** RP served as primary reviewer and provided an overview; AC was secondary reviewer.
- **Summary:** NH is investigating how B1 cell self-renewal is influenced by age and sex. The study examines natural antibody function differences between aged male and female mice and evaluates target genes involved in B1 cell renewal. CRISPR activation/interference will be used to manipulate genes in sorted B1 cells, delivered via Adeno-Associated Viral Vectors (AAV) subtype 8. Modified cells will be transferred into RAG mice for functional analysis over 12 weeks.
- **Containment:** Work will be conducted at BSL-2. AAV8 vectors are replication-incompetent and non-pathogenic in humans. Double containment will be used for transfers; all tissues and materials disposed of in biohazard bags.
- **Risk:** Low risk due to the use of recombinant AAV8 and CRISPR gene editing. No select agents involved. Viral particles require helper plasmids for assembly and are not replication competent.
- **Safety:** SOP for AAV work attached. PPE includes lab coat, gloves, surgical mask, and eye protection. All manipulations performed in a biosafety cabinet. Decontamination and waste disposal procedures in place.

MOTION: A motion was made by RV and seconded by AC to approve the protocol with the contingency that the following suggested changes are made.

Suggested changes:

- Section 6.1 – “AAV8 will be used to deliver CRISPRa/i constructs to either a) sorted B-1 cells in culture (in vitro application) or b) through venous injections into mice (in vivo application)” Clarify whether the AAV8 virus will be injected directly into mice when delivering CRISPRa/i constructs for the in vivo application.
- Section 7.5 – Specify the type of mask required (e.g., surgical, N95) and the circumstances under which masks will be worn
- Section 7.7 – Breakdown of biological sex of mice in animal numbers

VOTES: Approve

# Present	Votes For	Votes Against	Abstained	Recused	Absent
5	5	0	0	1	3

c. YL Personnel Amendment for IBC-2024-005 processed administratively

d. CJ Protocol Closure for IBC-2022-023 processed administratively

6. Radiation Safety Updates - PJ

- Dosimeters for the previous quarter were sent out; no personnel recorded doses near the limit. WMed North had no X-ray procedures during the quarter, so their dosimeters were not turned in.
- AC is completing training with PJ for RSO duties and will eventually complete a radiation safety course to meet the Nuclear Regulatory Commission (NRC) requirement of 40 hours of classroom instruction.
- The X-ray generator on the fifth floor has an issue with the door interlock and internal switch not engaging/disengaging. PJ contacted the company and they are scheduled to be on-site on September 10 to do an annual machine inspection.

PJ left at 10:53

7. Occupation Health Updates - JD

- Incident reporting software (Velocity EHS) initial kick off meeting on August 27th with a go live date before December 31st. This systems bring us into compliance for NIH reporting process.

8. Biosafety Updates - AC

- 5th Floor BSL-2 Status: Door signs are being generated to reflect work completed within each lab space.
- Training Updates: Auditing of all training records and chemical inventories across lab spaces is in progress.
- RSO Training: AC is completing Radiation Safety Officer training to serve as a backup to PJ.
- Professional Development: AC is considering upcoming ABSA courses, contingent on available funding.

9. Review of SOPs

- **Lead Acetate Trihydrate:**

- The Standard Operating Procedure (SOP) is complete, pending finalization of a waste disposal company.
- Disposal has been complicated due to the mixed nature of the waste (biohazard and chemical).
- Once the waste vendor is confirmed, any specific disposal procedures will be incorporated into the SOP, which will then be finalized for IBC.
- The IACUC protocol involving lead acetate work has been approved.

10. IBC General Updates:

- Annual Renewal Forms: NH and CJK will conduct an initial review of all protocols to assess exemption status.
- Confidentiality Agreement: A confidentiality agreement has been created for IBC committee members. All members are requested to sign and return the form.
- Stem Cell Committee: A new chair and community member are needed to fill current vacancies.
- October is Biosafety Month- AC will be hosting training workshops

11. Adjournment:

Meeting ended at 11:06am.